Bone Abstracts

Bisphosphonates (BPs) such as zoledronic acid (ZA) are widely used to treat bone diseases. The use of BPs can lead to osteonecrosis of the jaw (ONJ), but it is not clear why in particular the jaw bone is affected. Previously, it was shown that osteoclasts derived from different bone sites have different properties. We hypothesize that BPs have distinct effects on bone-site specific osteoclasts or precursors. To investigate this, female C57BL/6J mice were injected intraperitone...

Osteoclasts are multinucleated bone-resorbing cells and can be cultured from different monocytic precursors. It is unknown whether osteoclasts derived from different precursors are phenotypically different. One of the aspects not known is the life span of the different osteoclasts and the effect of IL-1β hereupon. Here, we studied this using time-lapse microscopy. Bone marrow cells were isolated from 6-week-old male mice. Early blasts (CD31hiLy-6C-),...

Bisphosphonates (BPs) are used to treat bone diseases characterized by excessive bone resorption. However, BPs can negatively affect the jaw bone by causing osteonecrosis of the jaw. Previously, we showed that BPs differently affect long-bone and jaw osteoclast precursors. Administration of BPs in vivo reduced the number of jaw bone marrow cells, without affecting long-bone marrow cells. Yet, BPs increased bone volume and mineral density of both long bone and jaw. Her...